ALIOF Stock Price, News & Analysis (OTCMKTS:ALIOF) $278.50 0.00 (0.00%) (As of 09/27/2022) Add Compare Share Share Today's Range$278.50▼$278.5050-Day Range$278.50▼$278.5052-Week Range$138.01▼$286.30VolumeN/AAverage Volume924 shsMarket Capitalization$29.89 billionP/E RatioN/ADividend YieldN/APrice TargetN/A About ALIOF Stock (OTCMKTS:ALIOF)Actelion Ltd. develops, produces and markets pharmaceutical drugs. The firm engages in research, development, manufacturing, and distribution of pharmaceutical, biological, and diagnostic products. The company was founded by Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Müller and Thomas Widmann on December 30, 1999 and is headquartered in Allschwil, Switzerland.Read More ALIOF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALIOF Stock News HeadlinesAugust 24, 2023 | thestreet.com5 Things You Must Know Before the Market Opens FridayMay 5, 2023 | msn.comIndia goes Digital: 5 major indicators of MASSIVE transformationDecember 9, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comApril 14, 2021 | reuters.com4th Circuit revives antitrust claims against Actelion over Tracleer pricingMarch 23, 2021 | theguardian.com'What appointments did these dogs have to keep?': long lunches and brief liaisons in a radical new dogumentaryDecember 12, 2020 | msn.comCollege Student Arrested in Delhi for Abducting Minor Girl After Befriending Her on FacebookJuly 23, 2020 | sg.finance.yahoo.comSynthetic Biologics Inc. (SYN) Looks Strong as Stock Gains 34.3%July 23, 2020 | sg.finance.yahoo.comStrength Seen in Amicus Therapeutics, Inc. (FOLD) as Stock Rallies 19.46%December 9, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comJanuary 17, 2019 | www.marketwatch.comActelion Receives Complete Response Letter from U.S. FDA for OPSUMIT® (Macitentan) Supplemental New Drug ApplicationSee More Headlines Receive ALIOF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ALIOF and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/16/2015Today12/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Medicinals & Botanicals Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ALIOF CUSIPN/A CIKN/A Webwww.actelion.com Phone(161) 565-6565Fax41-61-565-6500EmployeesN/AYear Founded1997Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares107,330,000Free FloatN/AMarket Cap$29.89 billion OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesNicholas FrancoChief Business Development Officer & EVPKey CompetitorsModernaNASDAQ:MRNAGE HealthCare TechnologiesNASDAQ:GEHCLonza GroupOTCMKTS:LZAGYargenxNASDAQ:ARGXBiogenNASDAQ:BIIBView All Competitors Should I Buy ALIOF Stock? ALIOF Pros and Cons Explained These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of ALIOF was last updated on Sunday, December 3, 2023 at 4:59 PM. Pros Here are some ways that investors could benefit from investing in ALIOF: Recent developments in ALIOF have shown positive growth potential, indicating a promising future for the company. ALIOF's latest product, the ALIOF X, has received positive reviews and is expected to drive sales and revenue. ALIOF's stock price has been steadily increasing over the past year, providing potential for capital appreciation. ALIOF has a strong financial position with a healthy balance sheet and positive cash flow, reducing the risk of financial instability. ALIOF has a diversified product portfolio, reducing reliance on any single product and providing stability in revenue streams. Cons Investors should be bearish about investing in ALIOF for these reasons: The competitive landscape in the industry is intense, with several well-established players, which may pose challenges for ALIOF's market share. ALIOF's latest financial reports show a decline in profitability, raising concerns about the company's ability to generate sustainable earnings. The global economic uncertainty and potential market volatility may impact ALIOF's sales and revenue growth. ALIOF's heavy reliance on a single market or region exposes it to geopolitical risks and regulatory changes that could negatively impact its operations. ALIOF's high debt levels may limit its flexibility in pursuing growth opportunities and increase its vulnerability to interest rate fluctuations. ALIOF Stock Analysis - Frequently Asked Questions How have ALIOF shares performed in 2023? ALIOF's stock was trading at $278.50 at the beginning of 2023. Since then, ALIOF shares have increased by 0.0% and is now trading at $278.50. View the best growth stocks for 2023 here. How were ALIOF's earnings last quarter? ALIOF (OTCMKTS:ALIOF) posted its quarterly earnings results on Monday, February, 16th. The company reported $0.87 EPS for the quarter, missing analysts' consensus estimates of $1.09 by $0.22. The firm had revenue of $501.50 million for the quarter, compared to the consensus estimate of $546.30 million. How do I buy shares of ALIOF? Shares of ALIOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (OTCMKTS:ALIOF) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALIOF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.